Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules.
about
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.
P2860
Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@ast
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@en
type
label
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@ast
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@en
prefLabel
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@ast
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@en
P2093
P2860
P1476
Interleukin-2 receptor-directe ...... ine-based targeting molecules.
@en
P2093
P2860
P304
P356
10.1111/J.1600-065X.1992.TB01422.X
P577
1992-10-01T00:00:00Z